Scienture Holdings, Inc., a pharmaceutical holding company, announced entering into a securities purchase agreement with institutional investors.
The agreement involves the purchase of 3,225,000 shares of common stock at $1.20 per share.
The gross proceeds from the offering are expected to be approximately $3.9 million before expenses. The offering is set to close on August 15, 2025.
Offer Details
3,225,000 shares of common stock to be sold at $1.20 per share.
Gross Proceeds
Approximately $3.9 million expected before deduction of expenses.
Closing Date
Offering expected to close on August 15, 2025, subject to customary conditions.
Placement Agent
Maxim Group LLC acts as the sole placement agent for the offering.
- The registered direct offering marks a significant move for Scienture Holdings in raising capital for its operations.
- The agreement with institutional investors indicates confidence in the company's pharmaceutical products and market potential.
The securities purchase agreement signifies a strategic step for Scienture Holdings in enhancing its financial position and advancing its pharmaceutical operations.